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Purpose: To investigate the relationship between vascular endothelial growth factor (VEGF) and the cancer stem 
cell-vascular niche complex in human retinoblastoma tissue.
Methods: Six human retinoblastoma specimens primarily enucleated for Reese-Ellsworth classification stage 5a 
were stained to detect cancer stem cell markers, including ABCG2 for the stem cell marker and MCM2 for the 
neural stem cell marker, as well as to detect VEGF for the angiogenic cytokine. Using immunofluorescence, the 
expression of these proteins was analyzed, and their relative locations noted. 
Results: In non-neoplastic retina of tumor-bearing eyes, ABCG2 and MCM2 were sporadically expressed in the 
ganglion cell layer and the inner nuclear layer, whereas VEGF was sporadically expressed in inner retina where 
retinal vessels are abundantly distributed. In the tumor, ABCG2 was strongly expressed out of Wintersteiner 
rosettes, whereas MCM2 and VEGF were strongly stained in the rosettes. Interestingly, the outer portion of the 
rosettes was positive for MCM2, and the inner portion of the rosettes was positive for VEGF.
Conclusions: Our data demonstrated that MCM2 and VEGF are strongly expressed in the rosettes of the tumor, 
which were far from the area of ABCG2-positive cells. Although VEGF might not directly contribute to the cancer 
stem cell-vascular niche complex, it could play some role in the differentiation of tumor cells to build up the 
rosettes.
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Cancer stem cells (CSCs) have been introduced and inves-
tigated as a new hypothesis of tumorigenesis in recent years  
[1, 2]. In this theory, a population of cells with stem cell- like 
characteristics, i.e. self-renewal, multipotency, and tumor ini-
tiation capability, exists in tumors. This population gives rise 
to the bulk of the tumor cells with more differentiated 
phenotypes. CSCs could be helpful not only in under-
standing the pathogenesis of the cancer, but also in the treat-
ment of the cancer itself. CSCs were regarded as the key 
component of chemoresistance of cancers, and it should be 
the target for drug development. Recent study revealed that 
selective targeting of CSCs is possible [3].
CSCs, like normal stem cells, are believed to exist within 
a protective perivascular niche, but can escape from the 
niche control. The presence of a perivascular niche was 
proved in the hematopoietic system, as well as in brain 
tumors [4,  5]. Calabrese et al. [5] suggest that CSCs in brain 
tumors, similar to neural stem cells, reside in vascular 
niches that are important targets for therapeutic approaches. 
A few orthotopic xenograft studies in brain tumors suggest 
that CSCs secrete angiogenic factors, such as vascular 
endothelial growth factor (VEGF), that promote the recr- 
uitment and formation of tumor blood vessels [5,  6]. 
Retinoblastoma is the most common intraocular child-
hood tumor [7]. Moreover, retinoblastoma is believed to be 
a good model in which to search for a tumor cell of origin 
and to understand the molecular pathogenesis of malignant 
tumors [8,  9]. Recent studies demonstrate that a small pro-
portion of human and mouse retinoblastoma cell populations 
express cancer stem cell markers (including ABCG2) and 
neural stem cell markers (including MCM2) [10,  11]. Zhong Korean J Ophthalmol Vol.24, No.1, 2010
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Fig.1. ABCG2, MCM2, and VEGF expression in the non-neoplastic retina of the human retinoblastoma eye. (A) ABCG2 was sporadically ex-
pressed in the ganglion cell layer and the inner nuclear layer. Original magnification ×20. (B) MCM2 positivity was observed in GCL and 
INL, similar to ABCG2. Original magnification ×20. (C) VEGF was also sporadically expressed in the inner retina. Original magnification ×20. 
VEFG=vascular endothelial growth factor; GCL=ganglion cell layer; IPL=inner plexiform layer; INL=inner nuclear layer; OPL=outer 
plexiform layer; ONL=outer nuclear layer.
et al. [12] demonstrated the presence of tumorigenic retinal 
stem-like cells that contribute to tumorigenesis in human 
retinoblastoma. 
Without regard to relation with cancer stem cells or a 
perivascular niche, VEGF has been studied as an important 
angiogenic growth factor in retinoblastoma [13,  14]. In 
recent studies, anti-angiogenic therapy targeting VEGF 
has been proposed as a promising new treatment strat-
egy of retinoblastoma [15-17].
In this study, we investigated the expression of ABCG2 
and MCM2 proteins in human retinoblastoma tissues 
and the correlation of their expression with VEGF pro-
teins, which may be related to the CSCs-perivascular 
niche complex. The purpose of this study was to eval-
uate the relation between VEGF and the cancer stem cell- 
vascular niche complex in human retinoblastoma tissue.
Materials and Methods
Patients
Six patients who were diagnosed as having unilateral 
highly progressive large retinoblastoma, group 5a in Reese- 
Ellsworth classification, were included in this study. All 
patients underwent enucleation without chemotherapy or 
focal therapies. All human retinoblastoma tissue samples 
were obtained with informed consent and in accordance 
with the tenets of the Declaration of Helsinki. 
Antibodies and chemicals
For the detection of ABCG2 protein, mouse monoclonal 
anti-ABCG2 antibody (1:100, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) was used. Primary goat polyclonal 
anti-MCM2 antibody (1:200, Santa Cruz Biotechnology) 
and primary rabbit polyclonal anti-VEGF antibody (1:100, 
Santa Cruz Biotechnology) were also used for staining. 
Immunofluorescence
Paraffin-embedded enucleated eyes were sectioned into 
4-μm sections. Sections of archival human specimens were 
rehydrated with xylene and graded alcohols. After washing 
in running water for five minutes, antigen retrieval was 
performed by placing slides in 10 mM sodium citrate 
buffer (pH 6.0), heated at 120℃ for 10 minutes. The slides 
and buffer were then cooled to room temperature for 30 
minutes. After washing with phosphate buffered saline 
(PBS), the slides were incubated with 0.2% Tripton 
X-100 for 15 minutes. After three rinses in PBS for five 
minutes each, sections were incubated with blocking 
solution for 30 minutes, followed by incubation with 
primary antibodies: five hours for ABCG2 and VEGF 
and two hours for MCM2. All sections were incubated 
for two hours with secondary antibody, followed by 
mounting. M Kim, et al. Stem cell markers and VEGF in retinoblastoma
37
A  B
C  D
E  F
Fig. 2. ABCG2, MCM2, and VEGF expression in retinoblastoma tumors. (A and B) ABCG2 was expressed outside of the Wintersteiner ro-
settes or tumor lobules. (C and D) MCM2 was strongly expressed in the rosettes and lobules, especially in the outer portion of the rosettes. (E 
and F) VEGF positivity was also observed in the rosettes of lobules, specifically in the inner portion of the rosettes. Original magnification 
×20 with A, C, and E. Original magnification ×40 with B, D, and F.  
Results
ABCG2, MCM2 and VEGF expression in the non- 
neoplastic retina
ABCG2 and MCM2 were sporadically expressed in the 
ganglion cell layer, the inner nuclear layer, and the photo-
receptor layer in the non-neoplastic portion of the retina 
of the tumor-bearing eye. Expression of these markers 
seemed not to be related with retinal vasculature (Fig. 1A 
and 1B).
VEGF was sporadically expressed in the inner retina Korean J Ophthalmol Vol.24, No.1, 2010
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where retinal vessels are abundantly distributed (Fig. 1C). 
ABCG2, MCM2 and VEGF expression in retinoblastoma 
tumors
ABCG2 was strongly expressed in the Wintersteiner 
rosettes or tumor lobules. In the rosettes or lobules, 
sporadic expression of ABCG2 was observed and not 
related to tumor vasculature. Most of ABCG2-stained 
cells were adjacent to the rosettes (Fig. 2A and 2B). 
MCM2 was strongly positive in the rosettes, especially 
in the outer portion of the rosettes (Fig. 2C and 2D). 
Within the lobules of the tumor, MCM2 was expressed 
around the blood vessels. 
VEGF was expressed in the rosettes or tumor lobules, 
similar to MCM2. But unlike MCM2, VEGF was strongly 
expressed in the inner portion of the rosettes (Fig. 2E and 
2F). In the lobules of retinoblastoma, VEGF was also 
sporadically expressed, but not directly associated with 
tumor vessels. 
Discussion
Evidence suggests that CSCs exist in human retinobl- 
astoma [10,  11,  18]. Seigel et al. [18] observed the pres-
ence of a small population which express a cancer stem 
cell marker (ABCG2) and a neural stem cell marker 
(MCM2) in tumors from transgenic mice, human retino-
blastoma cell lines, and human retinoblastomas. ABCG2 
is a half ATP-binding cassette transporter in the G2 subfamily 
that has been utilized to identify stem cells in several 
types of cancer. ABCG2 is also related to a resistance 
to a wide variety of anticancer drugs [19]. MCM2 is one 
of six members of the family of minichromosome main-
tenance proteins involved in initiating DNA replication [20]. 
MCM2 is a proven marker of neural stem cells and is 
known to be related to the aggressiveness of neuroecto- 
dermal tumors and retinoblastoma [11,  21].
In this study, the expression of ABCG2 and MCM2 in 
human archival retinoblastoma tumors and the non-neoplastic 
retina in the same eye was observed by immunofluorescence 
staining. Concurrent with previous studies, MCM2 pos-
itivity was observed surrounding blood vessels in both well- 
and poorly-differentiated tumor tissues. MCM2 was strongly 
positive in tumor rosettes. In normal retinas, MCM2 
positivity was observed in the ganglion cell layer, inner 
nuclear layer, and photoreceptor layer. The ABCG2 
staining pattern was similar in the normal retina. In 
retinoblastoma tumor tissues, on the other hand, ABCG2 
positivity was observed outside of the tumor rosettes 
and lobules. This result differed from previous reports. 
With our data, ABCG2 and MCM2 stained differ-
ent portions of the retinoblastoma tumor tissue. 
According to the cancer stem cell hypothesis, the cancer 
stem cell-vascular niche is an important aspect in understanding 
CSCs and in differentiating them from normal stem cells. 
Stem cells reside in “niches”, defined as physical spaces in 
the tissue used to maintain homeostasis [4]. CSCs might es-
cape from normal niche control, and the dysregulated 
stem cell division may give rise to turmor- igenesis. 
CSCs secrete angiogenic factors, such as VEGF, that pro-
mote the recruitment and formation of tumor vasculature [5,  6]. 
VEGF had been studied as an important regulator of 
physiologic and pathologic angiogenesis before the concept 
of CSCs emerged. VEGF expression in retinoblastoma 
has also been studied because retinoblastomas are highly 
vascularized tumors that are dependent on angiogen- esis 
[13,  14,  22]. Recent studies have revealed that VEGF- 
targeted treatments suppress tumor angiogenesis and 
growth significantly in retinoblastomas. In these studies, 
the anti- angiogenic effect by blocking VEGF was con- 
sidered the most important mode of action [15-17]. Until 
now, the mechanism of action with anti-VEGF agents 
has not been fully understood [23]. 
In this study, we speculate that VEGF is related to 
CSCs or the CSCs-perivascular niche complex. VEGF is 
known to be secreted from neoplastic cells and influences 
endothelial cells as paracrine mediators, but the relationship 
between VEGF and CSCs in retinoblastomas is unknown. 
We stained the VEGF protein in retinoblastoma tissues 
to locate the expression and to compare it to that of 
ABCG2 and MCM2. Consistent with previous studies, 
VEGF immunoreactivity was observed sporadically at 
the inner retina where there is abundant retinal vascula-
ture in the normal retina. However, this staining was 
weak and not directly related to retinal vasculature. In 
retinoblastoma tumor tissues, VEGF expression was 
observed in the rosettes or tumor lobules, similar to 
MCM2 expression. Unlike MCM2, strong VEGF expressed 
was observed in the inner portion of the rosettes. We 
have no immediate explanation for the difference in the 
distribution of these proteins. One possible reason that 
VEGF expression is observed at the inner portion of the 
rosettes is that it is a secretary protein. The lobules of 
the retinoblastoma also showed sporadic VEGF positivity 
but that was not directly associated with tumor vessels. 
If CSCs or the CSCs-perivascular niche have pivotal 
roles in VEGF secretion, VEGF immunopositivity must 
be observed in similar locations as CSC markers. Similarly, 
if VEGF directly contributes to the CSCs-perivascular 
niche complex, then VEGF must be located around the 
tumor vasculature. However, our data show that VEGF 
expression is not related to ABCG2 expression or tumor 
vasculature. Instead, VEGF expression was similar to that 
of MCM2 except with specific topographical distribution. 
Our study suggests that, although VEGF might not 
directly contribute to the CSC-perivascular niche complex, 
it could play some role in the differentiation of tumor 
cells and in rosette formation.M Kim, et al. Stem cell markers and VEGF in retinoblastoma
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